Strong 10-year investment returns (828.47% gain), robust revenue growth (38% YoY in 2025), successful partnerships with major pharma companies, and positive analyst sentiment with earnings estimate revisions. However, biosimilar competition and revenue concentration risks temper the outlook.
Strong recent price momentum (+3.3%), robust earnings growth expectations (+30.8% YoY), significant revenue growth (+32.9% YoY), positive earnings estimate revisions (+2.6% over 30 days), and successful collaboration deals generating royalty and milestone payments. Zacks Rank #2 (Buy) rating supports positive outlook.
Articles that tag HALO but are mainly about other companies.
Provides enabling drug delivery technology for oncology; ENHANZE platform demonstrates continued industry adoption with Pfizer nominating new target for study.
Halozyme is mentioned as a technology partner providing ENHANZE drug delivery technology for Acumen's subcutaneous formulation. This represents a collaboration opportunity but provides limited direct impact information.
Listed as a significant holding in RFG. Mentioned factually as part of the fund's portfolio composition without independent sentiment assessment.
Halozyme is mentioned as a technology partner providing ENHANZE drug delivery technology for a subcutaneous formulation. This represents a collaboration opportunity but does not directly impact Halozyme's business materially based on the information provided.
Halozyme's subsidiary Antares Pharma secured an exclusive telehealth partner to expand XYOSTED's market access and patient reach through a direct-to-patient model. This collaboration addresses key barriers to treatment adoption (fragmented care, cost unpredictability) and represents a strategic approach to commercializing the branded pharmaceutical product in an underserved market.
Halozyme is mentioned as a technology partner providing ENHANZE drug delivery technology for a subcutaneous formulation of sabirnetug. This represents a collaboration opportunity but carries no direct sentiment impact on Halozyme's business.
Halozyme is mentioned only as a technology partner providing ENHANZE drug delivery technology for a subcutaneous formulation being investigated by Acumen. This is a minor partnership mention with no material impact assessment.
Mentioned as a technology partner providing ENHANZE drug delivery technology for a subcutaneous formulation; this represents a collaboration opportunity but no direct business impact is disclosed.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
